Abstract
We report two cases of beta-thalassemia-induced osteoporosis. A man and a woman presented an osteoporosis at the densitometry and were treated with bisphoshonate iv. All the studies analysed the efficacity of bisphosphonate, in particular zoledronate seems to be effective. Concerning the pathogenesis, the RANK-RANK-Ligand and OPG play a major role in bone-resorption and seem to be the principal implicated mechanism for the development of osteoporosis in BTM. At the moment there is no study evaluating the efficacity of denosumab in the BTM.
MeSH terms
-
Absorptiometry, Photon
-
Adult
-
Antibodies, Monoclonal, Humanized / adverse effects
-
Antibodies, Monoclonal, Humanized / therapeutic use
-
Bone Density Conservation Agents / adverse effects
-
Bone Density Conservation Agents / therapeutic use*
-
Denosumab
-
Diphosphonates / adverse effects
-
Diphosphonates / therapeutic use*
-
Female
-
Humans
-
Hypogonadism / complications
-
Hypogonadism / drug therapy
-
Imidazoles / adverse effects
-
Imidazoles / therapeutic use
-
Infusions, Intravenous
-
Male
-
Osteoporosis / diagnosis
-
Osteoporosis / drug therapy*
-
Osteoporosis / etiology*
-
Zoledronic Acid
-
beta-Thalassemia / complications*
-
beta-Thalassemia / diagnosis
-
beta-Thalassemia / drug therapy*
Substances
-
Antibodies, Monoclonal, Humanized
-
Bone Density Conservation Agents
-
Diphosphonates
-
Imidazoles
-
Denosumab
-
Zoledronic Acid